Searched for
SHIONOGI PHARMA
Pharma in her DNA, Wockhardt scion ready for deep dive in the USZahabiya Khorakiwala is leading Wockhardt's US business and the launch of its new antibiotic, Zaynich. This drug targets resistant bacteria...- US stocks futures move as Dow, S&P 500, Nasdaq fluctuate on Trump’s tariffs and PCE inflation dataUS stock futures moved up and down as traders watched new tariff news and waited for an inflation report. Some big companies like Intel, El...
- Japan's Topix posts record-high close despite US tariffs on pharmaJapan's broad Topix index closed at an all-time high on Friday, despite pressure from pharmaceutical shares following new tariffs on the se...
- Japan's Topix hits record high despite US tariffs on pharmaJapan's Topix index reached a record high on Friday. This happened despite pharmaceutical shares facing pressure. The Nikkei index, however...
- Aurobindo to produce, supply long acting HIV treatment drugAurobindo Pharma will manufacture and supply long-acting injectable HIV treatment, cabotegravir, across 133 countries through a voluntary l...
- Japan's Nikkei snaps 7-day winning streak as US tariff worries weighNikkei witnessed a slight dip, ending a seven-session winning streak. Pharma stocks fell after Donald Trump's tariff announcement. Automake...
- Debt-free Orchid Pharma charts out growth planOrchid Pharma, backed by Dhanuka Group, focuses on cephalosporin antibiotics. Expansion plans include a new facility, Enmetazobactam launch...
- Orchid all set to generate enough cash to fund expansion plans: Manish Dhanuka“Three years back, when we started, we had a significant debt. But, today we are a debt-free company and we also have significant investmen...
- Japan's Nikkei ends at near 3-month low on global recession fearsInvestors globally are on edge as surging borrowing costs stoke fears of widespread recession, with most of the world's major central banks...
- Nikkei ends 2% higher on bargain-buying, led by tech shares"The Japanese market fell too much in the previous sessions because of concerns about the impact of the Omicron variant, which is affecting...
- Chief of Asia's largest pharmaceutical company urges transparency in virus vaccine rolloutTakeda, one of the world's biggest pharmaceutical companies, is not developing its own vaccine but has contracts with several firms to dist...
- Sun Pharma strikes distribution alliance with Mitsubishi Tanabe in JapanSun’s products are part of the long-listed and established prescription brands and includes Parlodel, Lamsil, Nitroderm and Lopressor.
- With an aim of expansion, pharma companies like Lupin and Torrent eyeing overseas acquisitionThey are scouting for niche manufacturing sites, promising experimental drugs, specialty firms in emerging markets and opportunities in the...
- Lupin in talks with Japan's Astellas, Shionogi to buy their off-patent drug brandsThe acquisition will result in a wider offering for Lupin in Japanese market where its sales last fiscal stood at Rs 1,364 crore.
- US court restrains Lupin from selling generic drug 'Fortamet'The US court, however, denied the motion of Shionogi for recall of Lupin's already distributed generic Fortamet during the two weeks of at-...
- Ranbaxy gets USFDA nod for generic version of ulcer drugDrug maker Ranbaxy Laboratories today said it has received approval from the US drug regulator for manufacturing and marketing the generic ...
- Experts call Ranbaxy sell off as good dealThe deal in which Ranbaxy Laboratories Ltd India's largest pharmaceutical company was sold off to a Japanese-based Daiichi Sankyo Co has be...
Load More
